Mayo Clinic: Sezary Syndrome trials
The registry lists 13 Sezary Syndrome studies with Mayo Clinic as lead sponsor. 0 are open to participants now and 9 have results posted.
Phase 1 5Phase 2 7Phase 3 1No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Pembrolizumab in Treating Patients With Stage IB-IV Mycosis FungoidesCompletedNCT03695471Phase 2Results posted
- Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT01261247Phase 2Results posted
- Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaCompletedNCT01075321Phase 1/2Results posted
- Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin LymphomaCompletedNCT00918333Phase 1/2Results posted
- Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With CancerCompletedNCT00661999Phase 3Results posted
- Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaCompletedNCT00474929Phase 1/2Results posted
- Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's LymphomaCompletedNCT00438802Phase 1Results posted
- Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous TreatmentCompletedNCT00436618Phase 2Results posted
- Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by ChemotherapyCompletedNCT00416624Phase 2Results posted
- Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin LymphomaCompletedNCT02652715Not applicable
- Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow TransplantWithdrawnNCT00898612
- Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's LymphomaCompletedNCT00897923
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By SurgeryCompletedNCT00004075Phase 1